Uniphos Enterprises reports zero revenue, ₹1.19 crore Q1 loss
Key highlights
- Uniphos Enterprises Limited reported zero revenue from operations in Q1 FY27, versus ₹26.14 crore in Q4 FY26.
- Total income was ₹0.16 crore in Q1 FY27 and was entirely derived from other income.
- Standalone net loss was ₹1.19 crore for the quarter ended 30 June 2026, with EPS of negative ₹0.17.
- Q1 FY27 operating revenue was down from ₹5.86 crore in the corresponding prior-year quarter.
powered by IRIS

Uniphos Enterprises Limited reported zero revenue from operations and a standalone net loss of ₹1.19 crore for the quarter ended 30 June 2026, compared with trading revenue of ₹26.14 crore in the preceding quarter. The result shows that all reported Q1 FY27 income of ₹0.16 crore came from other income rather than sales.
Know Uniphos Enterprises inside out
Results, valuation, peers and who's buying, in one view.
What did Uniphos Enterprises report for Q1 FY27?
Uniphos Enterprises reported revenue from operations of ₹0.00 crore for Q1 FY27. The unaudited standalone result, approved by the board on 12 August 2026, compares with ₹26.14 crore of trading revenue in Q4 FY26 and ₹5.86 crore in the corresponding quarter a year earlier.
Total income was ₹0.16 crore, or ₹16.46 lakh. Since the company recorded no operating revenue, this amount was entirely from other income. Total income had stood at ₹26.55 crore in the March 2026 quarter and ₹6.12 crore in the comparable year-earlier quarter.
The company recorded a pre-tax loss of ₹1.19 crore for the June 2026 quarter. Net loss was also ₹1.19 crore, with basic and diluted earnings per share of negative ₹0.17. The reported figures are standalone and unaudited, as disclosed in the quarterly filing.
Why did quarterly income fall to ₹0.16 crore?
The immediate reason for the decline was the absence of revenue from operations during the quarter. The available result disclosure identifies the prior-period operating receipts as trading revenue, while the June 2026 quarter did not report any sales or trading revenue.
As a result, the quarter's total income was limited to other income of ₹0.16 crore. The data provided does not specify the individual source of this other income, nor does it provide a management explanation for the absence of operating revenue. Therefore, the result establishes the reported outcome but does not support a conclusion on the underlying business reason.
The decline was substantial on both comparison bases. Revenue from operations fell from ₹26.14 crore in Q4 FY26 to nil, while the year-on-year comparison was against ₹5.86 crore. Total income also declined from ₹26.55 crore sequentially and ₹6.12 crore a year earlier.
How do the Q1 FY27 figures compare with earlier periods?
Q1 FY27 was markedly weaker in reported income terms than the preceding March quarter and the corresponding June quarter. The company moved from ₹26.14 crore of operating revenue in Q4 FY26 to zero in Q1 FY27, a 100% sequential decline in reported revenue from operations.
The supplied historical information also indicates that quarterly sales have been uneven. Uniphos Enterprises reported no sales in the quarter ended December 2025, while another disclosed period, the quarter ended September 2025, also recorded no sales despite a reported net profit. These past quarterly disclosures show that profit and sales have not necessarily moved together because other income and other line items can affect the final result.
The comparison also requires care because the supplied information includes conflicting third-party figures that show Q1 revenue of ₹47.69 crore and net profit of ₹5.36 crore. Those figures conflict with the board-approved unaudited standalone financial result for the quarter ended 30 June 2026, which reports nil revenue from operations and a ₹1.19 crore loss. The filed standalone result is the basis for the figures discussed here.
Got a follow-up? Ask IRIS
What does the result mean for investors and operations?
For investors, the central point is that no operating revenue was reported in the June quarter. This makes quarterly profitability dependent on non-operating income, if any, while the company still recorded a ₹1.19 crore loss. The negative EPS of ₹0.17 reflects that loss on a per-share basis.
The result also limits direct assessment of operating margins for Q1 FY27. With revenue from operations at zero, an operating margin based on sales is not meaningful from the disclosed quarterly figures. Likewise, the available data does not break down expenses, cash flow, segment performance, or the source of other income.
The broader significance is the sharp contrast with the immediately preceding quarter, when trading revenue was ₹26.14 crore. Investors assessing the company’s financial performance would need to distinguish between the reported standalone result and any data presented by third-party information services that is inconsistent with the regulatory filing.
When is the next reported update from Uniphos Enterprises?
The available corporate information listed a board meeting for results on 3 November 2026. That meeting was the next scheduled results-related event identified after the Q1 FY27 announcement, although the supplied material does not state the outcome or the financial period to be considered.
Uniphos Enterprises had announced its Q1 FY27 result on 12 August 2026, followed by a newspaper publication on 14 August 2026. The company also published an operational performance and quarterly growth update through a BSE corporate announcement dated 9 October 2026, according to the supplied investor-feed information, but no financial details from that update are provided here.
Conclusion
Uniphos Enterprises reported nil revenue from operations, total income of ₹0.16 crore and a standalone net loss of ₹1.19 crore in Q1 FY27. The outcome represents a sharp reduction from both the ₹26.14 crore of trading revenue reported in Q4 FY26 and ₹5.86 crore in the corresponding prior-year quarter, making the absence of operating sales the defining feature of the result.
The next item to watch is the company’s subsequent results-related board meeting, which was scheduled for 3 November 2026 in the supplied information. Investors will look for whether later disclosures provide operating-revenue figures, detail on the source of other income, and clearer context for the quarter with no reported sales.


